Lowest CSF CHI3L1 level found in the CIS group might further support this hypothesis, although patients with CIS (i.e., not fulfilling the diagnostic criteria of MS after the first episode consistent with demyelination) are probably at lower risk of progression to CDMS than before the implementation of 2017 revision of MS diagnostic criteria. The gene discussed is CHI3L1; the disease is in situ carcinoma.